Calidi 10-Q Discloses Going-Concern Doubt, NYSE Equity Deficiency and Executive Pay Deferrals
CLDI is trading near its 52-week low of $0.62 (0.3% above the low) on light trading volume (0.3× avg).
Summary
Calidi's Q3 10-Q shows $3.9 million of cash, a $3.6 million quarterly loss and explicit going-concern doubt, alongside a NYSE American equity deficiency notice and executive salary deferrals tied to closing a $5.0 million financing.
Key Events · Earnings and Guidance · CLDI
-
Going-Concern Doubt Disclosed
Management states substantial doubt about the ability to continue as a going concern within 12 months of issuance. At September 30, 2026, cash stood at $3.9 million with $0.2 million restricted, against a $3.6 million third-quarter net loss.
-
NYSE American Equity Deficiency
A September 21, 2026 notice said stockholders' equity of $3.1 million at June 30, 2026 was below the $4.0 million continued-listing standard. The company submitted a plan by the October 21 deadline and must regain compliance by March 21, 2028.
-
67% Headcount Cut for $3M Savings
The November 6, 2026 restructuring eliminates about 67% of headcount and is expected to generate roughly $3.0 million of annualized compensation savings, with de minimis one-time charges.
-
Executives Defer Salary Above $250K
Effective November 9, 2026, the CEO, CFO and CSO each take base salary at a $250,000 annualized rate. The remainder of their $535,000, $430,000 and $400,000 salaries is deferred until the earlier of two months or a financing of at least $5.0 million.
Analysis · CLDI · Life Sciences
Survival is now the central question for Calidi. The company closed September with $3.9 million of cash against a $3.6 million quarterly net loss and $10.8 million of nine-month operating burn, and management states there is substantial doubt about the company's ability to continue as a going concern within 12 months. Layered on top is a September 21 NYSE American notice that stockholders' equity of $3.1 million at June 30 fell short of the $4.0 million continued-listing standard; a compliance plan was due October 21, with a cure deadline of March 21, 2028. The November 6 restructuring cuts roughly 67% of headcount for about $3.0 million of annualized savings, and effective November 9 the CEO, CFO and CSO are deferring salary above a $250,000 annualized rate until a financing of at least $5.0 million closes or two months pass. Management is also evaluating strategic alternatives including a merger or business combination. Any equity raise would be heavily dilutive at a share price near its 52-week low.
How filings like this one have moved
In the 30 days to Nov 12, 2026, 47.3% of the 1873 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.17%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CLDI was trading at $0.62 on NYSE in the Life Sciences sector, with a market capitalization of approximately $2.3M. The 52-week trading range was $0.62 to $24.96. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.